Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBITDA (2016 - 2026)

Myriad Genetics has reported EBITDA over the past 17 years, most recently at -$5.7 million for Q4 2025.

  • Quarterly EBITDA rose 85.38% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$387.2 million through Dec 2025, down 213.78% year-over-year, with the annual reading at -$387.2 million for FY2025, 213.52% down from the prior year.
  • EBITDA was -$5.7 million for Q4 2025 at Myriad Genetics, up from -$23.3 million in the prior quarter.
  • Over five years, EBITDA peaked at -$5.7 million in Q4 2025 and troughed at -$329.2 million in Q2 2025.
  • The 5-year median for EBITDA is -$37.8 million (2024), against an average of -$55.0 million.
  • The largest YoY upside for EBITDA was 85.38% in 2025 against a maximum downside of 801.92% in 2025.
  • A 5-year view of EBITDA shows it stood at -$43.1 million in 2021, then dropped by 21.11% to -$52.2 million in 2022, then soared by 39.85% to -$31.4 million in 2023, then fell by 24.2% to -$39.0 million in 2024, then soared by 85.38% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBITDA are -$5.7 million (Q4 2025), -$23.3 million (Q3 2025), and -$329.2 million (Q2 2025).